It is effective to treat congenital TTP symptoms in mice (312) and acquired TTP symptoms in rats, where rADAMTS13 was able to overcome circulating inhibitors and reconstitute ADAMTS13 activity (313). The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.